Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in Neuropsychopharmacology

Retrieve available abstracts of 125 articles:
HTML format

Single Articles

    July 2021
  1. SMUCNY J, Dienel SJ, Lewis DA, Carter CS, et al
    Mechanisms underlying dorsolateral prefrontal cortex contributions to cognitive dysfunction in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 20. pii: 10.1038/s41386-021-01089.
    PubMed     Abstract available

  2. FERRARELLI F, Phillips ML
    PFC neuromodulation with theta burst stimulation to impact behavior and neural network activity in schizophrenia and bipolar disorder.
    Neuropsychopharmacology. 2021 Jul 7. pii: 10.1038/s41386-021-01086.

  3. GOLDWASER EL, Chiappelli J, Kvarta MD, Du X, et al
    White matter in prolonged glucocorticoid response to psychological stress in schizophrenia.
    Neuropsychopharmacology. 2021 Jul 1. pii: 10.1038/s41386-021-01077.
    PubMed     Abstract available

    June 2021
  4. AVRAM M, Grothe MJ, Meinhold L, Leucht C, et al
    Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia.
    Neuropsychopharmacology. 2021 Jun 29. pii: 10.1038/s41386-021-01070.
    PubMed     Abstract available

  5. TRONCHIN G, Akudjedu TN, Ahmed M, Holleran L, et al
    Correction to: Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.
    Neuropsychopharmacology. 2021 Jun 24. pii: 10.1038/s41386-021-01062.

    May 2021
  6. MODINOS G, Richter A, Egerton A, Bonoldi I, et al
    Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.
    Neuropsychopharmacology. 2021 May 3. pii: 10.1038/s41386-021-01019.
    PubMed     Abstract available

    April 2021
  7. SEITZ-HOLLAND J, Seethaler M, Makris N, Rushmore J, et al
    The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study.
    Neuropsychopharmacology. 2021 Apr 8. pii: 10.1038/s41386-021-00997.
    PubMed     Abstract available

    March 2021
  8. WENZEL J, Haas SS, Dwyer DB, Ruef A, et al
    Cognitive subtypes in recent onset psychosis: distinct neurobiological fingerprints?
    Neuropsychopharmacology. 2021 Mar 15. pii: 10.1038/s41386-021-00963.
    PubMed     Abstract available

  9. PENZEL N, Antonucci LA, Betz LT, Sanfelici R, et al
    Association between age of cannabis initiation and gray matter covariance networks in recent onset psychosis.
    Neuropsychopharmacology. 2021 Mar 3. pii: 10.1038/s41386-021-00977.
    PubMed     Abstract available

    February 2021
  10. CHOPRA S, Fornito A, Francey SM, O'Donoghue B, et al
    Differentiating the effect of antipsychotic medication and illness on brain volume reductions in first-episode psychosis: A Longitudinal, Randomised, Triple-blind, Placebo-controlled MRI Study.
    Neuropsychopharmacology. 2021 Feb 26. pii: 10.1038/s41386-021-00980.
    PubMed     Abstract available

  11. MAAS DA, Eijsink VD, van Hulten JA, Panic R, et al
    Antioxidant treatment ameliorates prefrontal hypomyelination and cognitive deficits in a rat model of schizophrenia.
    Neuropsychopharmacology. 2021 Feb 9. pii: 10.1038/s41386-021-00964.
    PubMed     Abstract available

    January 2021
  12. SMUCNY J, Tully LM, Howell AM, Lesh TA, et al
    Schizophrenia and bipolar disorder are associated with opposite brain reward anticipation-associated response.
    Neuropsychopharmacology. 2021 Jan 15. pii: 10.1038/s41386-020-00940.
    PubMed     Abstract available

  13. LIANG S, Wang Q, Greenshaw AJ, Li X, et al
    Aberrant triple-network connectivity patterns discriminate biotypes of first-episode medication-naive schizophrenia in two large independent cohorts.
    Neuropsychopharmacology. 2021 Jan 6. pii: 10.1038/s41386-020-00926.
    PubMed     Abstract available

    December 2020
  14. STERTZ L, Di Re J, Pei G, Fries GR, et al
    Convergent genomic and pharmacological evidence of PI3K/GSK3 signaling alterations in neurons from schizophrenia patients.
    Neuropsychopharmacology. 2020 Dec 7. pii: 10.1038/s41386-020-00924.
    PubMed     Abstract available

  15. QUINONES GM, Mayeli A, Yushmanov VE, Hetherington HP, et al
    Reduced GABA/glutamate in the thalamus of individuals at clinical high risk for psychosis.
    Neuropsychopharmacology. 2020 Dec 3. pii: 10.1038/s41386-020-00920.
    PubMed     Abstract available

    November 2020
  16. DESAI A, Benner L, Wu R, Gertsik L, et al
    Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D1 receptor positive allosteric modulator in patients with schizophrenia.
    Neuropsychopharmacology. 2020 Nov 17. pii: 10.1038/s41386-020-00908.
    PubMed     Abstract available

    October 2020
  17. HAAS SS, Antonucci LA, Wenzel J, Ruef A, et al
    A multivariate neuromonitoring approach to neuroplasticity-based computerized cognitive training in recent onset psychosis.
    Neuropsychopharmacology. 2020 Oct 7. pii: 10.1038/s41386-020-00877.
    PubMed     Abstract available

  18. VALLE-LEON M, Callado LF, Aso E, Cajiao-Manrique MM, et al
    Decreased striatal adenosine A2A-dopamine D2 receptor heteromerization in schizophrenia.
    Neuropsychopharmacology. 2020 Oct 3. pii: 10.1038/s41386-020-00872.
    PubMed     Abstract available

    September 2020
  19. TAMMINGA CA, Clementz BA, Pearlson G, Keshavan M, et al
    Biotyping in psychosis: using multiple computational approaches with one data set.
    Neuropsychopharmacology. 2020 Sep 26. pii: 10.1038/s41386-020-00849.
    PubMed     Abstract available

  20. GALLEGO JA, Blanco EA, Morell C, Lencz T, et al
    Complement component C4 levels in the cerebrospinal fluid and plasma of patients with schizophrenia.
    Neuropsychopharmacology. 2020 Sep 22. pii: 10.1038/s41386-020-00867.
    PubMed     Abstract available

  21. VERONESE M, Santangelo B, Jauhar S, D'Ambrosio E, et al
    A potential biomarker for treatment stratification in psychosis: evaluation of an [(18)F] FDOPA PET imaging approach.
    Neuropsychopharmacology. 2020 Sep 22. pii: 10.1038/s41386-020-00866.
    PubMed     Abstract available

  22. SWERDLOW NR, Bhakta S, Talledo J, Kotz J, et al
    Memantine effects on auditory discrimination and training in schizophrenia patients.
    Neuropsychopharmacology. 2020 Sep 22. pii: 10.1038/s41386-020-00865.
    PubMed     Abstract available

  23. MYLONAS D, Baran B, Demanuele C, Cox R, et al
    The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized clinical trial.
    Neuropsychopharmacology. 2020 Sep 12. pii: 10.1038/s41386-020-00833.
    PubMed     Abstract available

    August 2020
  24. NAKAO K, Singh M, Sapkota K, Hagler BC, et al
    GSK3beta inhibition restores cortical gamma oscillation and cognitive behavior in a mouse model of NMDA receptor hypofunction relevant to schizophrenia.
    Neuropsychopharmacology. 2020 Aug 28. pii: 10.1038/s41386-020-00819.
    PubMed     Abstract available

  25. KOSHIYAMA D, Miyakoshi M, Joshi YB, Molina JL, et al
    A distributed frontotemporal network underlies gamma-band synchronization impairments in schizophrenia patients.
    Neuropsychopharmacology. 2020 Aug 22. pii: 10.1038/s41386-020-00806.
    PubMed     Abstract available

  26. MURPHY M, Ongur D
    EEG microstate sequences suggest abnormally chaotic brain dynamics in psychosis.
    Neuropsychopharmacology. 2020 Aug 14. pii: 10.1038/s41386-020-00800.

    July 2020
  27. CHENG PWC, Chang WC, Lo GG, Chan KWS, et al
    The role of dopamine dysregulation and evidence for the transdiagnostic nature of elevated dopamine synthesis in psychosis: a positron emission tomography (PET) study comparing schizophrenia, delusional disorder, and other psychotic disorders.
    Neuropsychopharmacology. 2020 Jul 1. pii: 10.1038/s41386-020-0740.
    PubMed     Abstract available

  28. QIN Z, Zhang L, Cruz SA, Stewart AFR, et al
    Activation of tyrosine phosphatase PTP1B in pyramidal neurons impairs endocannabinoid signaling by tyrosine receptor kinase trkB and causes schizophrenia-like behaviors in mice.
    Neuropsychopharmacology. 2020 Jul 1. pii: 10.1038/s41386-020-0755.
    PubMed     Abstract available

    June 2020
  29. BOUDEWYN M, Scangos K, Ranganath C, Carter CS, et al
    Using prefrontal transcranial direct current stimulation (tDCS) to enhance proactive cognitive control in schizophrenia.
    Neuropsychopharmacology. 2020 Jun 30. pii: 10.1038/s41386-020-0750.
    PubMed     Abstract available

  30. XIA Y, Zhang Z, Lin W, Yan J, et al
    Modulating microglia activation prevents maternal immune activation induced schizophrenia-relevant behavior phenotypes via arginase 1 in the dentate gyrus.
    Neuropsychopharmacology. 2020 Jun 29. pii: 10.1038/s41386-020-0743.
    PubMed     Abstract available

  31. CLARK SD, Van Snellenberg JX, Lawson JM, Abi-Dargham A, et al
    Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials.
    Neuropsychopharmacology. 2020 Jun 9. pii: 10.1038/s41386-020-0730.
    PubMed     Abstract available

    May 2020
  32. TROUDET R, Ali WBH, Bacq-Daian D, Rossum IWV, et al
    Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses.
    Neuropsychopharmacology. 2020 May 25. pii: 10.1038/s41386-020-0703.
    PubMed     Abstract available

  33. KANTROWITZ JT, Grinband J, Goff DC, Lahti AC, et al
    Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers.
    Neuropsychopharmacology. 2020 May 13. pii: 10.1038/s41386-020-0706.
    PubMed     Abstract available

  34. BUSTILLO JR, Upston J, Mayer G, Jones T, et al
    Glutamatergic hypo-function in the left superior and middle temporal gyri in early schizophrenia: a data-driven three-dimensional proton spectroscopic imaging study.
    Neuropsychopharmacology. 2020 May 13. pii: 10.1038/s41386-020-0707.
    PubMed     Abstract available

    April 2020
  35. XIA L, Liu L, Hong X, Wang D, et al
    One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.
    Neuropsychopharmacology. 2020 Apr 29. pii: 10.1038/s41386-020-0685.
    PubMed     Abstract available

  36. YAO L, Li F, Liu J, Liao W, et al
    Correction: Functional brain networks in never-treated and treated long-term Ill schizophrenia patients.
    Neuropsychopharmacology. 2020 Apr 17. pii: 10.1038/s41386-020-0673.
    PubMed     Abstract available

  37. TRONCHIN G, Akudjedu TN, Ahmed M, Holleran L, et al
    Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment.
    Neuropsychopharmacology. 2020 Apr 8. pii: 10.1038/s41386-020-0665.
    PubMed     Abstract available

    February 2020
  38. YAN Z, Schmidt SNL, Frank J, Witt SH, et al
    Hyperfunctioning of the right posterior superior temporal sulcus in response to neutral facial expressions presents an endophenotype of schizophrenia.
    Neuropsychopharmacology. 2020 Feb 14. pii: 10.1038/s41386-020-0637.
    PubMed     Abstract available

  39. KANTROWITZ JT, Javitt DC, Freedman R, Sehatpour P, et al
    Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients.
    Neuropsychopharmacology. 2020 Feb 3. pii: 10.1038/s41386-020-0628.
    PubMed     Abstract available

    January 2020
  40. TANI H, Takasu S, Uchida H, Suzuki T, et al
    Correction: Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.
    Neuropsychopharmacology. 2020 Jan 23. pii: 10.1038/s41386-019-0598.
    PubMed     Abstract available

  41. CHADHA R, Meador-Woodruff JH
    Downregulated AKT-mTOR signaling pathway proteins in dorsolateral prefrontal cortex in Schizophrenia.
    Neuropsychopharmacology. 2020 Jan 17. pii: 10.1038/s41386-020-0614.
    PubMed     Abstract available

  42. YU H, Cheng W, Zhang X, Wang X, et al
    Integration analysis of methylation quantitative trait loci and GWAS identify three schizophrenia risk variants.
    Neuropsychopharmacology. 2020 Jan 7. pii: 10.1038/s41386-020-0605.
    PubMed     Abstract available

    December 2019
  43. GIRGIS RR, Forbes A, Abi-Dargham A, Slifstein M, et al
    A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.
    Neuropsychopharmacology. 2019 Dec 17. pii: 10.1038/s41386-019-0590.
    PubMed     Abstract available

  44. TARUMI R, Tsugawa S, Noda Y, Plitman E, et al
    Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study.
    Neuropsychopharmacology. 2019 Dec 16. pii: 10.1038/s41386-019-0589.
    PubMed     Abstract available

    November 2019
  45. AMOAH SK, Rodriguez BA, Logothetis CN, Chander P, et al
    Exosomal secretion of a psychosis-altered miRNA that regulates glutamate receptor expression is affected by antipsychotics.
    Neuropsychopharmacology. 2019 Nov 27. pii: 10.1038/s41386-019-0579.
    PubMed     Abstract available

  46. TANI H, Takasu S, Uchida H, Suzuki T, et al
    Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.
    Neuropsychopharmacology. 2019 Nov 26. pii: 10.1038/s41386-019-0573.
    PubMed     Abstract available

  47. MIZUNO Y, McCutcheon RA, Brugger SP, Howes OD, et al
    Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis.
    Neuropsychopharmacology. 2019 Nov 25. pii: 10.1038/s41386-019-0577.
    PubMed     Abstract available

    October 2019
  48. LEMVIGH CK, Jepsen JRM, Fagerlund B, Pagsberg AK, et al
    Auditory sensory gating in young adolescents with early-onset psychosis: a comparison with attention deficit/hyperactivity disorder.
    Neuropsychopharmacology. 2019 Oct 24. pii: 10.1038/s41386-019-0555.
    PubMed     Abstract available

  49. HOWES OD, Bonoldi I, McCutcheon RA, Azis M, et al
    Glutamatergic and dopaminergic function and the relationship to outcome in people at clinical high risk of psychosis: a multi-modal PET-magnetic resonance brain imaging study.
    Neuropsychopharmacology. 2019 Oct 16. pii: 10.1038/s41386-019-0541.
    PubMed     Abstract available

  50. ANTONUCCI LA, Penzel N, Pergola G, Kambeitz-Ilankovic L, et al
    Multivariate classification of schizophrenia and its familial risk based on load-dependent attentional control brain functional connectivity.
    Neuropsychopharmacology. 2019 Oct 3. pii: 10.1038/s41386-019-0532.
    PubMed     Abstract available

    September 2019
  51. TAMMINGA CA, Clementz BA
    Biological fingerprints for psychosis.
    Neuropsychopharmacology. 2019 Sep 26. pii: 10.1038/s41386-019-0505.

  52. HUANG AS, Rogers BP, Anticevic A, Blackford JU, et al
    Correction: Brain function during stages of working memory in schizophrenia and psychotic bipolar disorder.
    Neuropsychopharmacology. 2019 Sep 2. pii: 10.1038/s41386-019-0488.
    PubMed     Abstract available

    August 2019
  53. SWERDLOW NR, Bhakta SG, Talledo J, Benster L, et al
    Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients.
    Neuropsychopharmacology. 2019 Aug 24. pii: 10.1038/s41386-019-0495.
    PubMed     Abstract available

  54. HO NF, Holt DJ, Cheung M, Iglesias JE, et al
    Correction: Progressive decline in hippocampal CA1 volume in individuals at ultra-high-risk for psychosis who do not remit: findings from the longitudinal youth at risk study.
    Neuropsychopharmacology. 2019 Aug 14. pii: 10.1038/s41386-019-0477.
    PubMed     Abstract available

  55. DUNCAN LE, Ostacher M, Ballon J
    How genome-wide association studies (GWAS) made traditional candidate gene studies obsolete.
    Neuropsychopharmacology. 2019;44:1518-1523.

    July 2019
  56. HOMAN P, Argyelan M, Fales CL, Barber AD, et al
    Striatal volume and functional connectivity correlate with weight gain in early-phase psychosis.
    Neuropsychopharmacology. 2019 Jul 17. pii: 10.1038/s41386-019-0464.
    PubMed     Abstract available

  57. KARCHER NR, Hua JPY, Kerns JG
    Striatum-related functional activation during reward- versus punishment-based learning in psychosis risk.
    Neuropsychopharmacology. 2019 Jul 4. pii: 10.1038/s41386-019-0455.
    PubMed     Abstract available

    June 2019
  58. LEUCHT S, Chaimani A, Mavridis D, Leucht C, et al
    Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis.
    Neuropsychopharmacology. 2019 Jun 18. pii: 10.1038/s41386-019-0440.
    PubMed     Abstract available

  59. HUANG AS, Rogers BP, Anticevic A, Blackford JU, et al
    Brain function during stages of working memory in schizophrenia and psychotic bipolar disorder.
    Neuropsychopharmacology. 2019 Jun 11. pii: 10.1038/s41386-019-0434.
    PubMed     Abstract available

  60. YAO L, Li F, Liu J, Liao W, et al
    Functional brain networks in never-treated and treated long-term Ill schizophrenia patients.
    Neuropsychopharmacology. 2019 Jun 4. pii: 10.1038/s41386-019-0428.
    PubMed     Abstract available

  61. KRAGULJAC NV, Anthony T, Monroe WS, Skidmore FM, et al
    A longitudinal neurite and free water imaging study in patients with a schizophrenia spectrum disorder.
    Neuropsychopharmacology. 2019 Jun 1. pii: 10.1038/s41386-019-0427.
    PubMed     Abstract available

    May 2019
  62. QUARMLEY M, Gur RC, Turetsky BI, Watters AJ, et al
    Reduced safety processing during aversive social conditioning in psychosis and clinical risk.
    Neuropsychopharmacology. 2019 May 21. pii: 10.1038/s41386-019-0421.
    PubMed     Abstract available

  63. DE COSTER L, Lin L, Mathalon DH, Woolley JD, et al
    Neural and behavioral effects of oxytocin administration during theory of mind in schizophrenia and controls: a randomized control trial.
    Neuropsychopharmacology. 2019 May 18. pii: 10.1038/s41386-019-0417.
    PubMed     Abstract available

  64. RAMMOS A, Gonzalez LAN, Weinberger DR, Mitchell KJ, et al
    The role of polygenic risk score gene-set analysis in the context of the omnigenic model of schizophrenia.
    Neuropsychopharmacology. 2019 May 11. pii: 10.1038/s41386-019-0410.
    PubMed     Abstract available

  65. JACOBS GR, Ameis SH, Lisa Ji J, Viviano JD, et al
    Developmentally divergent sexual dimorphism in the cortico-striatal-thalamic-cortical psychosis risk pathway.
    Neuropsychopharmacology. 2019 May 6. pii: 10.1038/s41386-019-0408.
    PubMed     Abstract available

    April 2019
  66. TAPIAS-ESPINOSA C, Rio-Alamos C, Sanchez-Gonzalez A, Oliveras I, et al
    Schizophrenia-like reduced sensorimotor gating in intact inbred and outbred rats is associated with decreased medial prefrontal cortex activity and volume.
    Neuropsychopharmacology. 2019 Apr 16. pii: 10.1038/s41386-019-0392.
    PubMed     Abstract available

    March 2019
  67. LEUCHT S, Barabassy A, Laszlovszky I, Szatmari B, et al
    Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Neuropsychopharmacology. 2019 Mar 5. pii: 10.1038/s41386-019-0363.
    PubMed     Abstract available

  68. BITTER I, Lieberman JA, Gaudoux F, Sokoloff P, et al
    Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia.
    Neuropsychopharmacology. 2019 Mar 1. pii: 10.1038/s41386-019-0355.
    PubMed     Abstract available

    February 2019
  69. KRUIPER C, Glenthoj BY, Oranje B
    Effects of clonidine on MMN and P3a amplitude in schizophrenia patients on stable medication.
    Neuropsychopharmacology. 2019 Feb 23. pii: 10.1038/s41386-019-0351.
    PubMed     Abstract available

  70. MCKINNEY BC, MacDonald ML, Newman JT, Shelton MA, et al
    Density of small dendritic spines and microtubule-associated-protein-2 immunoreactivity in the primary auditory cortex of subjects with schizophrenia.
    Neuropsychopharmacology. 2019 Feb 22. pii: 10.1038/s41386-019-0350.
    PubMed     Abstract available

  71. MAHMOUDI E, Fitzsimmons C, Geaghan M, Shannon Weickert C, et al
    Circular RNA biogenesis is decreased in postmortem cortical gray matter in schizophrenia and may alter the bioavailability of associated miRNA.
    Neuropsychopharmacology. 2019 Feb 20. pii: 10.1038/s41386-019-0348.
    PubMed     Abstract available

  72. STJEPAN C, Gregor L, Stephanie T, Christina A, et al
    Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.
    Neuropsychopharmacology. 2019 Feb 6. pii: 10.1038/s41386-019-0328.
    PubMed     Abstract available

    January 2019
  73. HOMAN P, Argyelan M, DeRosse P, Szeszko P, et al
    Structural similarity networks predict clinical outcome in early-phase psychosis.
    Neuropsychopharmacology. 2019 Jan 24. pii: 10.1038/s41386-019-0322.
    PubMed     Abstract available

  74. DAVIES C, Paloyelis Y, Rutigliano G, Cappucciati M, et al
    Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.
    Neuropsychopharmacology. 2019 Jan 9. pii: 10.1038/s41386-018-0311.
    PubMed     Abstract available

  75. WYNN JK, Green MF, Hellemann G, Reavis EA, et al
    A dose-finding study of oxytocin using neurophysiological measures of social processing.
    Neuropsychopharmacology. 2019;44:289-294.
    PubMed     Abstract available

    December 2018
  76. BRUCATO G, Appelbaum PS, Masucci MD, Rolin S, et al
    Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness.
    Neuropsychopharmacology. 2018 Dec 27. pii: 10.1038/s41386-018-0304.
    PubMed     Abstract available

  77. SHAHAB S, Mulsant BH, Levesque ML, Calarco N, et al
    Brain structure, cognition, and brain age in schizophrenia, bipolar disorder, and healthy controls.
    Neuropsychopharmacology. 2018 Dec 20. pii: 10.1038/s41386-018-0298.
    PubMed     Abstract available

    November 2018
  78. TAKEUCHI H, Siu C, Remington G, Fervaha G, et al
    Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia.
    Neuropsychopharmacology. 2018 Nov 22. pii: 10.1038/s41386-018-0278.
    PubMed     Abstract available

    October 2018
  79. HOCHBERGER WC, Joshi YB, Thomas ML, Zhang W, et al
    Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia.
    Neuropsychopharmacology. 2018 Oct 30. pii: 10.1038/s41386-018-0256.
    PubMed     Abstract available

  80. VANOVER KE, Davis RE, Zhou Y, Ye W, et al
    Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.
    Neuropsychopharmacology. 2018 Oct 26. pii: 10.1038/s41386-018-0251.
    PubMed     Abstract available

  81. SCHWEIGER JI, Bilek E, Schafer A, Braun U, et al
    Effects of BDNF Val(66)Met genotype and schizophrenia familial risk on a neural functional network for cognitive control in humans.
    Neuropsychopharmacology. 2018 Oct 25. pii: 10.1038/s41386-018-0248.
    PubMed     Abstract available

  82. LEGIND CS, Broberg BV, Mandl RCW, Brouwer R, et al
    Heritability of cerebral glutamate levels and their association with schizophrenia spectrum disorders: a (1)[H]-spectroscopy twin study.
    Neuropsychopharmacology. 2018 Oct 9. pii: 10.1038/s41386-018-0236.
    PubMed     Abstract available

  83. GONCALVES VF, Cuperfain AB, Kennedy JL
    Sex differences in schizophrenia: estrogen and mitochondria.
    Neuropsychopharmacology. 2018 Oct 7. pii: 10.1038/s41386-018-0228.

  84. MODINOS G, Simsek F, Azis M, Bossong M, et al
    Correction: Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology. 2018 Oct 2. pii: 10.1038/s41386-018-0118.
    PubMed     Abstract available

    September 2018
  85. SONNENSCHEIN SF, Gill KM, Grace AA
    State-dependent effects of the D2 partial agonist aripiprazole on dopamine neuron activity in the MAM neurodevelopmental model of schizophrenia.
    Neuropsychopharmacology. 2018 Sep 18. pii: 10.1038/s41386-018-0219.
    PubMed     Abstract available

  86. BOGART LJ, O'Donnell P
    Multiple long-range inputs evoke NMDA currents in prefrontal cortex fast-spiking interneurons.
    Neuropsychopharmacology. 2018;43:2101-2108.
    PubMed     Abstract available

    August 2018
  87. CHUNG DW, Chung Y, Bazmi HH, Lewis DA, et al
    Altered ErbB4 splicing and cortical parvalbumin interneuron dysfunction in schizophrenia and mood disorders.
    Neuropsychopharmacology. 2018 Aug 2. pii: 10.1038/s41386-018-0169.
    PubMed     Abstract available

    July 2018
  88. SHAKORY S, Watts JJ, Hafizi S, Da Silva T, et al
    Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.
    Neuropsychopharmacology. 2018 Jul 28. pii: 10.1038/s41386-018-0163.
    PubMed     Abstract available

  89. FAAY MDM, Czobor P, Sommer IEC
    Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis.
    Neuropsychopharmacology. 2018 Jul 23. pii: 10.1038/s41386-018-0161.
    PubMed     Abstract available

  90. RAJAGOPAL L, Huang M, Michael E, Kwon S, et al
    TPA-023 attenuates subchronic phencyclidine-induced declarative and reversal learning deficits via GABAA receptor agonist mechanism: possible therapeutic target for cognitive deficit in schizophrenia.
    Neuropsychopharmacology. 2018 Jul 23. pii: 10.1038/s41386-018-0160.
    PubMed     Abstract available

    June 2018
  91. ULIANA DL, Resstel LBM, Grace AA
    Fear extinction disruption in a developmental rodent model of schizophrenia correlates with an impairment in basolateral amygdala-medial prefrontal cortex plasticity.
    Neuropsychopharmacology. 2018 Jun 23. pii: 10.1038/s41386-018-0128.
    PubMed     Abstract available

    May 2018
  92. HOLPER L, Ben-Shachar D, Mann JJ
    Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.
    Neuropsychopharmacology. 2018 May 16. pii: 10.1038/s41386-018-0090.
    PubMed     Abstract available

  93. NOUR MM, McCutcheon R, Howes OD
    The Relationship Between Dopamine Synthesis Capacity and Release: Implications for Psychosis.
    Neuropsychopharmacology. 2018;43:1195-1196.

    April 2018
  94. NEVES GA, Grace AA
    alpha7 Nicotinic receptor-modulating agents reverse the hyperdopaminergic tone in the MAM model of schizophrenia.
    Neuropsychopharmacology. 2018 Apr 19. pii: 10.1038/s41386-018-0066.
    PubMed     Abstract available

  95. CHIAPPELLI J, Rowland LM, Notarangelo FM, Wijtenburg SA, et al
    Salivary kynurenic acid response to psychological stress: inverse relationship to cortical glutamate in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 18. pii: 10.1038/s41386-018-0072.
    PubMed     Abstract available

  96. HAFIZI S, Da Silva T, Meyer JH, Kiang M, et al
    Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study.
    Neuropsychopharmacology. 2018 Apr 13. pii: 10.1038/s41386-018-0061.
    PubMed     Abstract available

  97. AVRAM M, Brandl F, Bauml J, Sorg C, et al
    Cortico-thalamic hypo- and hyperconnectivity extend consistently to basal ganglia in schizophrenia.
    Neuropsychopharmacology. 2018 Apr 12. pii: 10.1038/s41386-018-0059.
    PubMed     Abstract available

  98. ERMAKOVA AO, Knolle F, Justicia A, Bullmore ET, et al
    Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis.
    Neuropsychopharmacology. 2018 Apr 5. pii: 10.1038/s41386-018-0056.
    PubMed     Abstract available

    Larry J Seidman.
    Neuropsychopharmacology. 2018;43:1189-1190.

    March 2018
  100. DOGAN AE, Yuksel C, Du F, Chouinard VA, et al
    Brain lactate and pH in schizophrenia and bipolar disorder: a systematic review of findings from magnetic resonance studies.
    Neuropsychopharmacology. 2018 Mar 14. pii: 10.1038/s41386-018-0041.
    PubMed     Abstract available

    February 2018
  101. CHIAPPELLI J, Notarangelo FM, Pocivavsek A, Thomas MAR, et al
    Influence of plasma cytokines on kynurenine and kynurenic acid in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 27. pii: 10.1038/s41386-018-0038.
    PubMed     Abstract available

  102. O'DONOVAN SM, Sullivan C, Koene R, Devine E, et al
    Cell-subtype-specific changes in adenosine pathways in schizophrenia.
    Neuropsychopharmacology. 2018 Feb 26. pii: 10.1038/s41386-018-0028.
    PubMed     Abstract available

  103. BARNETT I, Torous J, Staples P, Sandoval L, et al
    Relapse prediction in schizophrenia through digital phenotyping: a pilot study.
    Neuropsychopharmacology. 2018 Feb 22. pii: 10.1038/s41386-018-0030.
    PubMed     Abstract available

  104. BERNSTEIN HG, Dobrowolny H, Keilhoff G, Bogerts B, et al
    Reduced Density of DISC1 Expressing Astrocytes in the Dentate Gyrus but not in the Subventricular Zone in Schizophrenia.
    Neuropsychopharmacology. 2018;43:457-458.

  105. ALLSWEDE DM, Zheutlin AB, Chung Y, Anderson K, et al
    Complement Gene Expression Correlates with Superior Frontal Cortical Thickness in Humans.
    Neuropsychopharmacology. 2018;43:525-533.
    PubMed     Abstract available

    January 2018
  106. MODINOS G, Simsek F, Azis M, Bossong M, et al
    Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.
    Neuropsychopharmacology. 2018 Jan 30. pii: 10.1038/s41386-017-0004.
    PubMed     Abstract available

  107. YOUNG JW, Light GA
    Cross-Species Neurophysiological Biomarkers of Attentional Dysfunction in Schizophrenia: Bridging the Translational Gap.
    Neuropsychopharmacology. 2018;43:230-231.

    December 2017
  108. DOYLE GA, Berrettini WH
    Failure to Replicate an Association of a LINE-1 Element in ERI1 Exoribonuclease Family Member 3 (ERI3) with Schizophrenia.
    Neuropsychopharmacology. 2017;42:2471.

    November 2017
  109. PERKINS KA, Chengappa KR, Karelitz JL, Boldry MC, et al
    Initial Cross-Over Test of a Positive Allosteric Modulator of Alpha-7 Nicotinic Receptors to Aid Cessation in Smokers with or Without Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 29. pii: npp2017292. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  110. SWERDLOW NR, Bhakta SG, Talledo JA, Franz DM, et al
    Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.
    Neuropsychopharmacology. 2017 Nov 20. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  111. NAGELS A, Cabanis M, Oppel A, Kirner-Veselinovic A, et al
    S-Ketamine-Induced NMDA Receptor Blockade During Natural Speech Production and its Implications for Formal Thought Disorder in Schizophrenia: A Pharmaco-fMRI Study.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  112. STEFANIK L, Erdman L, Ameis SH, Foussias G, et al
    Brain-Behavior Participant Similarity Networks Among Youth and Emerging Adults with Schizophrenia Spectrum, Autism Spectrum, or Bipolar Disorder and Matched Controls.
    Neuropsychopharmacology. 2017 Nov 6. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  113. GIRGIS RR, Ciarleglio A, Choo T, Haynes G, et al
    A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Tocilizumab, an Interleukin-6 Receptor Antibody, for Residual Symptoms in Schizophrenia.
    Neuropsychopharmacology. 2017 Nov 1. doi: 10.1038/npp.2017.
    PubMed     Abstract available

    September 2017
  114. SMUCNY J, Lesh TA, Newton K, Niendam T, et al
    Levels of Cognitive Control: A Functional Magnetic Resonance Imaging-Based Test of an RDoC Domain Across Bipolar Disorder and Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 26. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  115. RAMSAY IS, Fryer S, Boos A, Roach BJ, et al
    Response to Targeted Cognitive Training Correlates with Change in Thalamic Volume in a Randomized Trial for Early Schizophrenia.
    Neuropsychopharmacology. 2017 Sep 12. doi: 10.1038/npp.2017.
    PubMed     Abstract available

    August 2017
  116. KEM WR, Olincy A, Johnson L, Harris J, et al
    Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation.
    Neuropsychopharmacology. 2017 Aug 21. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  117. O'DONNELL P
    Microglia Activation in Subjects at Risk for Psychosis, Fact or Fiction?
    Neuropsychopharmacology. 2017 Aug 18. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  118. LEE M, Balla A, Sershen H, Sehatpour P, et al
    Rodent Mismatch Negativity (MMN)/Theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
    Neuropsychopharmacology. 2017 Aug 17. doi: 10.1038/npp.2017.
    PubMed     Abstract available

    July 2017
  119. BRUCATO G, Appelbaum PS, Lieberman JA, Wall MM, et al
    A Longitudinal Study of Violent Behavior in a Psychosis-Risk Cohort.
    Neuropsychopharmacology. 2017 Jul 26. doi: 10.1038/npp.2017.
    PubMed     Abstract available

    June 2017
  120. COSGROVE D, Mothersill O, Kendall K, Konte B, et al
    Cognitive Characterization of Schizophrenia Risk Variants Involved in Synaptic Transmission: Evidence of CACNA1C's Role in Working Memory.
    Neuropsychopharmacology. 2017 Jun 13. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  121. HAFIZI S, Da Silva T, Gerritsen C, Kiang M, et al
    Imaging Microglial Activation in Individuals at Clinical High Risk for Psychosis: An In-Vivo PET Study with [18F]FEPPA.
    Neuropsychopharmacology. 2017 Jun 12. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  122. DOYLE GA, Crist RC, Karatas ET, Hammond MJ, et al
    Analysis of LINE-1 Elements in DNA from Postmortem Brains of Individuals with Schizophrenia.
    Neuropsychopharmacology. 2017 Jun 6. doi: 10.1038/npp.2017.
    PubMed     Abstract available

    April 2017
  123. RABIN RA, Barr MS, Goodman MS, Herman Y, et al
    Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia versus Non-Psychiatric Controls.
    Neuropsychopharmacology. 2017 Apr 26. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  124. LIGHT GA, Zhang W, Joshi YB, Bhakta S, et al
    Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
    Neuropsychopharmacology. 2017 Apr 20. doi: 10.1038/npp.2017.
    PubMed     Abstract available

  125. EISENBERG DP, Yankowitz L, Ianni AM, Rubinstein DY, et al
    Presynaptic Dopamine Synthesis Capacity in Schizophrenia and Striatal Blood Flow Change During Antipsychotic Treatment and Medication-Free Conditions.
    Neuropsychopharmacology. 2017 Apr 7. doi: 10.1038/npp.2017.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.